Radiopharmaceuticals are beginning to revolutionise cancer care and Novartis is the current leader in the space, driven by their focus on one of the new “beta” emitters, lutetium-177. In their latest video Novartis are discussing limitations of their products, including the reliance on a small, ageing fleet of nuclear reactors and complex and fragile supply chains. With a focus on copper-67, Clarity is also the world leader in the new “betas”, differentiating itself from the pack with its Targeted Copper Theranostics (TCTs) platform and resolving the challenges associated with other “betas”. Copper isotopes are ideally suited for radiopharmaceuticals, allow central manufacture of diagnostics and therapies on cyclotrons and electron accelerators, respectively. They enable broad distribution, while being infinitely scalable in all geographies of the world. This allows the full expansion of radiopharmaceuticals into the very large oncology space and, importantly, provides access to patients with cancer and their oncologists around the globe. Click here to watch the video: https://lnkd.in/gdhnEwmi
Clarity Pharmaceuticals
Biotechnology Research
Sydney, NSW 9,066 followers
Clarity is developing next-generation products to address the growing need for radiopharmaceuticals in oncology.
About us
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
- Website
-
http://www.claritypharmaceuticals.com
External link for Clarity Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Sydney, NSW
- Type
- Public Company
- Founded
- 2010
- Specialties
- Antibody and peptide imaging, Pharmaceutical imaging, Companion diagnostics, Drug development, Radiopharmaceuticals, Nuclear medicine, and Targeted therapy
Locations
-
Primary
National Innovation Centre
4 Cornwallis Street
Sydney, NSW 2015, AU
Employees at Clarity Pharmaceuticals
Updates
-
Clarity signs supply agreement for actinium-225 with TerraPower Isotopes for its 225Ac-bisPSMA program. We are excited to complement our best in class PSMA targeting therapy, 67Cu-SAR-bisPSMA, with a Targeted Alpha-particle Therapy, aiming to provide more options for people with prostate cancer at different stages of their disease. This places Clarity in a unique position to fundamentally transform and broaden the arsenal of treatments available for oncologists and their patients as we pursue our ultimate goal of improving treatment outcomes for people with cancer. Click here to read more: https://lnkd.in/gmS9zaBU
-
Answering all of the hard questions on investors’ minds, Clarity's Executive Chairperson, Dr Alan Taylor, joined fund manager and Clarity shareholder Frazis Capital Partners Pty Ltd Michael Frazis to discuss the intricacies of the radiopharmaceutical market as it becomes the hottest area in oncology, covering its players, trends, products, challenges and the enormous opportunities that lie ahead for radiopharmaceuticals. #radiopharmaceuticals #biotech #oncology
Clarity Pharmaceuticals with Dr Alan Taylor: the next generation of radiopharmaceuticals
https://www.youtube.com/
-
Copper-64 and copper-67 are ideally suited for diagnosis and treatment of cancer and offer a number of advantages, including logistical, manufacturing and environmental benefits. This differentiates Targeted Copper Theranostics from a myriad of other radiopharmaceuticals and enables Clarity to employ the big pharma model of centralised manufacturing of both diagnostic and therapeutic products under cGMP under one roof. Watch season 2 episode 5 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the "perfect pairing" of copper isotopes and how it is positioned to launch radiopharmaceuticals into the large oncology market, overcoming numerous challenges of the current-generation of diagnostics and therapies. #podcast #radiopharmaceuticals #biotech
-
Clarity's novel SAR-bisPSMA agent was developed at the benchtop utilising some of the best Australian science to fix limitations associated with the current-generation of PSMA products. The clinical data we are seeing now with both diagnostic and therapeutic applications of SAR-bisPSMA offers new hope to patients with prostate cancer and their clinicians. Watch season 2 episode 4 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about Clarity's optimised dual-targeting PSMA agent, SAR-bisPSMA, the science behind it, the incredible data we are seeing to date and the benefits it could offer to patients in the future. #podcast #biotech #radiopharmaceuticals
-
This June has been momentous for Clarity as its data was presented at major conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the Jefferies Healthcare Conference in New York, and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto. Radiopharmaceuticals continue to be one of the hottest areas in oncology, however, a number of challenges prevail, including the lack of innovation with reliable supply of products that are both efficacious and have a favourable safety profile. At the conferences, the message was clear: Clarity stands in sharp contrast to its peers. Listen to the Principal Investigator of the theranostic Phase I/IIa trial, SECuRE, Geoff Johnson, MD, PhD, from the Mayo Clinic, as he discusses Clarity’s 67Cu-SAR-bisPSMA product that uses the novel dual-PSMA targeting molecule SAR-bisPSMA, enabling increased uptake and retention of the product in tumours. Dr Johnson also provides an update on the current status of the SECuRE trial with some of the incredible results to date. As Clarity has a range of additional products in the clinic and a number of new targets in its pre-clinical and discovery pipeline, leveraging its strong proprietary position in radiopharmaceuticals, the Company would like to thank all of its team and collaborators for the opportunity to work with great people along the shared goal of better treating children and adults with cancer.
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in mCRPC | GU Oncology Now
guoncologynow.com
-
Clarity strengthens Cu-64 network with new supply agreement with SpectronRx to ensure seamless supply of the diagnostic isotope for Clarity’s products which continue to progress through clinical trials, including a pivotal Phase III clinical trial in prostate cancer. Click here to read more: https://lnkd.in/gS2xz9Un #diagnostics #radiopharmaceuticals
-
There has been a lot of interest around radioisotopes in radiopharmaceuticals. But what is just hype and what will bring real hope to patients? Watch season 2 episode 3 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the different radioisotopes, their pros and cons, recent acquisitions in the space and the future of radiopharm. #podcast #biotech #radiopharmaceuticals
-
As big pharma companies are rushing to get their toes in the waters of the radiopharmaceutical field, the sector is as hot as ever. With accelerated M&A activity in this space, Clarity continues to focus on strengthening three key pillars that differentiate it from the myriad of others: best-in-class product pipeline with excellent safety and efficacy data to date, strong intellectual property, and seamless supply & manufacturing. Watch season 2 episode 2 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about the radiopharmaceutical field and Clarity's competitive advantages in the space #podcast #biotech #radiopharmaceuticals
-
The Science Hat, a podcast series about science and innovation in the radiopharmaceutical space, is back for season 2. Watch episode 1 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about Clarity Pharmaceuticals' most recent capital raise and where it places the company in the current biotech market. #TCT #biotech #radiopharmaceuticals